May 14, 2015

Trevena Announces Presentation of Preclinical Data for Delta Receptor Compound TRV250 at International Headache Congress

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced that data highlighting its preclinical TRV250 program will be presented in an oral presentation at the International Headache Congress being held in Valencia, Spain, May 14-17, 2015.

“Our preclinical data suggests TRV250 may safely activate the delta receptor in the central nervous system, and could become a first-in-class therapy for migraine and other CNS disorders,” said Maxine Gowen, Ph.D., chief executive officer. “TRV250 is Trevena’s fourth biased ligand product candidate in development, which highlights the productivity of our platform in delivering differentiated new chemical entities targeting important unmet clinical needs.”

Aimee Crombie, Ph.D., director of chemistry, will give an oral presentation entitled “TRV250: a novel biased ligand at the delta receptor for the potential treatment of migraine” in a session scheduled for 10:00 - 11:00 a.m. local time on Friday, May 15. The presentation will describe the preclinical profile of TRV250 and its actions at the delta opioid receptor, a CNS target with potential benefits in migraine and other CNS disorders. Previous efforts to develop selective delta receptor ligand drugs have been hindered by seizure risk which, in Trevena studies, was associated with delta receptor signals mediated by the scaffold protein β-arrestin2. Compared to previously described ligands, TRV250 elicits markedly reduced β-arrestin2 recruitment to the delta receptor. TRV250 is active in models of acute and chronic migraine as well as models of depression, anxiety, and pain, including pain associated with central sensitization. TRV250 displayed very broad safety margins in multiple preclinical species, and is not expected to have addiction or abuse liability associated with mu-opioid agonists like morphine and oxycodone.

About TRV250

TRV250 is an oral delta receptor biased ligand with promise as a migraine therapy, with a potential first-in-class mechanism that may benefit treatment-refractory patients who cannot take or do not benefit from triptan drugs. TRV250 may also have utility in a range of other CNS indications, and targets a receptor that is not associated with the addiction liability of mu opioid drugs like morphine or oxycodone.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (preclinical).

Cautionary Note on Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the company, including statements about the company's strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the company's clinical trials; the uncertainties inherent in conducting clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or results of pre-clinical testing or early clinical trials will be indicative of the results of future trials, including whether existing pre-clinical data for TRV250 will be replicated in any future clinical studies; expectations for regulatory approvals; availability of funding sufficient for the company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the viability or commercial potential of the company's therapeutic candidates; the inherent uncertainties associated with intellectual property; and other factors discussed in the Risk Factors set forth in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the company's views only as of the date hereof. The company anticipates that subsequent events and developments may cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

Investor Contacts:

Trevena, Inc.
Jonathan Violin
Director of investor relations
610-354-8840 x231
jviolin@trevenainc.com
or
Argot Partners
Andrea Rabney
President and chief executive officer
212-600-1902
andrea@argotpartners.com
or

Media Contact:
Argot Partners
Eliza Schleifstein
917-763-8106
eliza@argotpartners.com

Source: Trevena, Inc.